As with astrogliosis, the genetic or pharmacological blockade of mGlu5 in AD and ALS rodent models led to a reduction in microgliosis (Bonifacino et al., 2017; Abd-Elrahman K. S. et al., 2020; Milanese et al., 2021). Here, GRM5 is linked to Alzheimer disease.